Once stimulated, the epidermal growth factor receptor (EGFR) undergoes self-phosphorylation, which, on the one hand, instigates signaling cascades, and on the other hand, recruits CBL ubiquitin ligases, which mark EGFRs for degradation. Using RNA interference screens, we identified a deubiquitinating enzyme, Cezanne-1, that opposes receptor degradation and enhances EGFR signaling. These functions require the catalytic-and ubiquitin-binding domains of Cezanne-1, and they involve physical interactions and transphosphorylation of Cezanne-1 by EGFR. In line with the ability of Cezanne-1 to augment EGF-induced growth and migration signals, the enzyme is overexpressed in breast cancer. Congruently, the corresponding gene is amplified in approximately one third of mammary tumors, and high transcript levels predict an aggressive disease course. In conclusion, deubiquitination by Cezanne-1 curtails degradation of growth factor receptors, thereby promotes oncogenic growth signals.
INTRODUCTION
Binding of EGF to the cognate transmembrane receptor, epidermal growth factor receptor (EGFR), stimulates the intrinsic tyrosine kinase activity and culminates in cell fate decisions. Importantly, these positively acting processes are coupled to a web of negatively acting feedback loops. 1 One robust and early feedback loop entails targeting activated EGFRs to degradation in lysosomes, or to an escape recycling route. 2 EGFR transfer from endosomes back to the plasma membrane is thought to enhance intracellular signaling. 3 --5 The regulation of receptor trafficking and the underlying intracellular signals appear complex and redundant. Sorting at the plasma membrane is executed by adaptors of clathrin, the phosphotyrosine-binding protein GRB2 3 and the kinase inhibitor RALT/MIG6. 6 By contrast, sorting at the multi-vesicular body, a pre-lysosomal compartment, depends on an E3 ligase molecule called CBL. 7, 8 Upon tyrosine phosphorylation, CBL modifies multiple lysine residues, located within the kinase domain of EGFR, with monomeric, 9, 10 as well as with polymeric ubiquitin molecules. 7 Ubiquitin moieties attached to EGFR are then recognized by a set of ubiquitin-binding adapters of the clathrin coat (for example, Epsin). These adapters harbor ubiquitin-binding domains (UBDs), and thereby assemble active receptors at clathrin-coated regions of the plasma membrane, endosomes and the multi-vesicular body. 11 Although they are topologically different, the sorting assemblies (called: endosomal sorting complexes required for transport) share a mechanism of cargo dissociation and reloading: at the endosome, E3 ligases of the AIP4/Nedd4 family ubiquitinate the ubiquitin binders, for example HRS (Hepatocyte growth factor-regulated tyrosine kinase Substrate), to promote their intramolecular folding in a way that dissociates the cargo and enables loading of a new receptor upon their de-ubiquitination. 12, 13 Enzymatic deubiquitination of the endocytic machinery, as well as deubiquitination of receptor molecules, have essential regulatory roles. 14 Approximately 100 DUBs are known that fall into five classes: ubiquitin C-terminal hydrolases, the ubiquitin-specific proteases, Josephins, the JAB1/MPN/MOV3 metalloenzymes and the ovarian tumor proteases. At least three DUBs are involved, either directly or indirectly, in EGFR endocytosis. The best characterized is AMSH, a JAB1/MPN/MOV3 metalloenzymes family member whose knockdown leads to enhanced degradation of EGFR. 15, 16 Targeting of AMSH to endosomes may occur via clathrin 17 or by endosomal sorting complexes required for transport-III. 18 The roles for another endosomal DUB, UBPY (USP8), deviate from a simple model of receptor deubiquitination, as this enzyme is involved in stabilization of two endosomal sorting components, HRS and STAM, and it destabilizes EGFR. 19 A third DUB-regulating EGFR, namely USP18, functions at the level of protein translation. 20 This study assumed that yet uncovered DUBs regulate EGFR endocytosis, hence applied screens of siRNA libraries to EGF-stimulated cells. In addition to AMSH, our screen identified an ovarian tumor proteases family member, Cezanne-1, as an enzyme able to stabilize ligand-activated EGFRs. In agreement with the ability of Cezanne-1 to enhance receptor signaling, we found that the expression of the corresponding gene, from a locus frequently amplified in tumors, predicts short survival of the breast cancer patients.
RESULTS

siRNA screens identify Cezanne proteins as EGFR-specific DUBs
To identify EGFR-regulating enzymes, we performed siRNA screens of the majority of human DUBs. (listed under Supplementary Table 1) . Because EGFR is expressed in epithelial cell types, we assumed that the putative DUB is co-expressed in epithelial tumor cells, such as KB oral cells. Hence, we transfected KB cells with siRNA duplexes against different DUBs, and stimulated the cells with EGF. This strategy was confirmed by transfecting KB cells with siRNA oligonucleotides specific to AMSH (as a positive control), or USP19, as a negative control. Ligand-induced degradation of EGFR was moderately enhanced upon AMSH knockdown, consistent with previous reports 16, 18 ( Figure 1a ). In addition to AMSH, our screens of 95 human DUBs identified Cezanne-1, a DUB previously implicated in nuclear factor-kb signaling, 21, 22 and its family member, Cezanne-2, as candidate DUBs of EGFR (Figure 1b) . Accordingly, simultaneous knockdown of Cezanne-1 and -2 by using two pools of four oligonucleotides (B70% and 50%, respectively) moderately enhanced both basal and inducible degradation of EGFR, whereas the reciprocal silencing of c-CBL and CBL-b showed the expected opposite effect (Figure 1c ). After 48 h, cells were stimulated with EGF (20 ng/ml) for the depicted intervals. Thereafter, whole cell extracts were immunoblotted with the indicated antibodies, including antibodies to the phosphorylated forms of AKT and extracellular signal-regulated kinase (ERK), as well as antibodies specific to specific phosphorylated tyrosines of EGFR. Signal intensities of phosphorylated AKT and ERK2 were quantified, normalized and graphically presented (right panels). All panels presented in this figure were repeated at least thrice.
Because Cezanne-1 is frequently overexpressed in cancer cells (see below), but Cezanne-2 displays no extensive alterations, we focused on Cezanne-1. To extend the effects beyond KB cells to other Cezanne-1-expressing cell, we used the widely used HeLa cells, which were co-transfected with plasmids encoding Cezanne-1 and a Flag-tagged ubiquitin. The results presented in Figure 1d confirmed that Cezanne-1 overexpression associates with remarkably reduced ubiquitination of EGFR, as well as with stabilization the receptor and an increase in auto-phosphorylation. Application of a reciprocal approach in HeLa cells, which used specific siRNAs, confirmed that knockdown of Cezanne-1 correlates with accelerated degradation and decreased receptor phosphorylation. Moreover, diminished phosphorylation of AKT and extracellular signalregulated kinase type 1/2 was detected (Figure 1e) . Notably, silencing Cezanne-1 inactivated EGFR's kinase before receptor degradation, probably due to enhanced ubiquitination that either disabled the enzyme or occluded lysine acceptors of ubiquitin. In conclusion, our genetic screens and validation tests indicated that Cezanne-1 regulates EGFR levels, as well as downstream signals.
Cezanne-1 stabilizes and physically interacts with EGFR Cezanne-1 and -2 belong to the family of Otubains, which harbor a catalytically active deubiquitinating domain and two UBDs: a ubiquitin-associated domain (UBA) and an A20-like Zinc Finger (ZnF; Figure 2a ). To study the functions of Cezanne-1, we generated a set of mutants: The catalytic cysteine of active deubiquitinating domain was replaced by a serine, generating a catalytically inactive mutant (C194S). Likewise, we deleted the UBA and the ZnF (DUBA and DZnF). Previous studies defined the A20-like ZnF of Rabex-5 as a UBD that uses a diaromatic patch to recognize a polar region centered on Asp58 of ubiquitin. 23 Hence, we also mutated the respective diaromatic patch of Cezanne-1 (mutants denoted F809A and Y810A). Comparison of Cezanne-1 WT and C194S confirmed that overexpression of WT caused stabilization of EGFR following stimulation with EGF, but C194S accelerated EGFR degradation, in line with functionality of the catalytic domain ( Figure 2b ).
Next, we sought to determine whether Cezanne-1 and EGFR maintain bi-directional enzyme --substrate interactions. As a first Thereafter, cleared cell extracts were subjected to immunoprecipitation (IP) with the indicated antibodies or directly electrophoresed. An arrow indicates a form of EGFR whose mobility is retarded. This experiment was repeated thrice. (d) The indicated forms of HA-Flag-tagged Cezanne-1 were co-expressed together with EGFR in HEK-293T cells. After 48 h transfection, cells were treated for 10 min with increasing concentrations of EGF (0, 10 and 50 ng/ml) and cell lysates subjected to IP and immunoblotting (IB) using the indicated antibodies.
step, we overexpressed WT and C194S, along with EGFR, in HEK-293T cells. In addition, to enhance ubiquitination, we also transfected c-CBL, and stimulated the cells under conditions that partly inhibit EGFR degradation. This experiment suggested that both forms of Cezanne-1 can co-immunoprecipitate with the unstimulated EGFR molecule, and this interaction can be enhanced upon EGF stimulation (Figure 2c ). Co-expression of c-CBL, which leads to increased receptor ubiquitination, further strengthened the interaction. Interestingly, C194S displayed slightly weaker coprecipitation. Nevertheless, when combined with c-CBL, this mutant precipitated a high molecular weight form of EGFR, probably the ubiquitinated version (marked by an arrow; Figure 2c ). These observations implied that Cezanne-1 preassembles with EGFR molecules. Upon activation by EGF, these interactions are enhanced, probably due to receptor ubiquitination. In line with this model, when we co-expressed EGFR and Cezanne-1 under conditions that inhibit receptor degradation due to overexpression, we observed EGF-induced tyrosine phosphorylation of Cezanne-1 ( Figure 2d ). Importantly, a mutant lacking the ZnF lost the ability to undergo inducible phosphorylation, but the catalytically defective C194S mutant retained tyrosine phosphorylation. These observations predicted rapid onset of EGFR --Cezanne complexes, followed by dissociation due to deubiquitination. Indeed, in a coimmunoprecipitation experiment of the endogenous EGFR and Cezanne-1, the peak time of complex formation was reached 5 min after stimulation, and this was followed by a rapid decay (Figure 3a ). In conclusion, EGF-induced and CBL-mediated ubiquitination of EGFR permit phosphorylation Immunoprecipitates were immunoblotted with antibodies against EGFR and Cezanne-1. Whole cell extracts were probed with antibodies to EGFR, Cezanne-1 and extracellular signal-regulated kinase type 2 (ERK2). (b) HeLa cells were transfected with plasmids encoding Cezanne-1, either WT or C194S, together with a Flag-tagged ubiquitin. Thereafter, cells were stimulated with EGF (20 ng/ml). Cell extracts were subjected to IP and/or immunoblotting (IB) with the indicated antibodies. (c) HeLa cells were transfected with a mixture of siRNAs against Cezanne-1 and -2 or with control oligonucleotides. After 48 h transfection, cells were incubated with EGF (20 ng/ml) and lysates were subjected to IP and immunoblotting as indicated. Signals were quantified, normalized and the ubiquitin/EGFR ratio indicated. (d) HeLa cells were stimulated for 15 min with EGF (20 ng/ml). Subsequently, cells were lysed and their extracts subjected to IP with anti-EGFR antibodies. Thereafter, EGFR immunoprecipitates were incubated for 1 h at 37 1C with the WT or C194S forms of a His-tagged Cezanne-1, previously purified from bacteria. The immunoprecipitates were subsequently immunoblotted with antibodies against ubiquitin and EGFR; signals were quantified, normalized and their ratio presented. (e) HeLa cells were transfected with plasmids encoding the indicated forms of Cezanne-1 or with an empty vector. Thereafter, cells were stimulated with EGF (2 ng/ml) for the indicated time intervals. Next, EGFR downregulation was assayed using a radioactive EGF. Averages of triplicates and s.d. values (bars) are presented. All experiments presented in this figure were repeated at least thrice.
and recruitment of Cezanne-1 to multiple ubiquitins, but subsequent deubiquitination by Cezanne-1 dissociates the complex.
Deubiquitination of EGFR by Cezanne-1 inhibits receptor downregulation To ascertain the effect of Cezanne-1 on EGFR ubiquitination, HeLa cells were co-transfected with plasmids encoding Cezanne-1, either WT or a catalytically inactive mutant, and a Flag-tagged ubiquitin. The results presented in Figure 3b confirmed the necessity of the catalytic function of Cezanne-1 for deubiquitination of EGFR. The reciprocal experiment, in which we knockeddown both Cezanne-1 and -2 detected increased ubiquitin/ receptor ratios and enhanced rates of receptor degradation (Figure 3c ). In summary, the combination of gain-and loss-offunction approaches lent support to the conclusion that Cezanne family proteins regulate the level of EGFR ubiquitination.
To validate enzyme --substrate relations, we performed in vitro deubiquitination experiments. HeLa cells were stimulated with EGF, and EGFR was immunoprecipitated. In parallel, recombinant forms of a His-tagged Cezanne-1 (WT and C194S) were purified from bacteria, and incubated with the immunoprecipitated receptor. Blotting for ubiquitinated receptors confirmed that Cezanne-1 WT can deubiquitinate EGFR in vitro. In contrast, C194S showed no evidence of activity ( Figure 3d ). Next, we analyzed the effects of Cezanne-1-mediated deubiquitination on receptor endocytosis. HeLa cells were stimulated for up to 2 h with physiological concentrations of EGF (2 ng/ml), and receptors remaining on the cell surface were quantified with a radioactive EGF. Overexpression of Cezanne-1 WT inhibited receptor downregulation at all time intervals. In contrast, both C194S and DZnF exerted no inhibitory effects and a third mutant, DUBA, resembled the phenotype induced by WT (Figure 3e and data not shown). In conclusion, the deubiquitinating and ubiquitin-binding function of Cezanne-1 enable rescue of EGFR from intracellular degradation.
The Zinc Finger of Cezanne-1 interacts with the non-canonical ubiquitin face centered on aspartate 58 Although many UBDs recognize the canonical surface of ubiquitin centered on Ile-44, ubiquitin may also be recognized via an Asp-58-centered interface. 23, 24 To determine the specificity of the ZnF, we used mutants of the diaromatic motif of the ZnF of Cezanne-1, the putative Asp-58 interfacing site, as well as ubiquitins mutated at Ile-44 and Asp-58. As a first step, we incubated cell extracts containing Cezanne-1 (WT or FY/AA) with bacterially expressed glutathione S-transferase (GST) fusion proteins of ubiquitin (Ub; WT, D58A or I44A). The results of this experiment indicated that the WT form of Cezanne-1 specifically binds with either surface of ubiquitin, presumably because the UBA recognizes Ile-44 whereas the ZnF binds with Asp-58. This model was supported by the observed inability of FY/AA to recognize Ub-I44A (Figure 4a ). Further support was provided by an experiment that tested individual ZnF mutants: F809A (which bound Ub-I44A) and Y810A, which practically lost the ability to recognize Ub-I44A (Figure 4b ). To determine the affinity of monoubiquitin binding to the ZnF, we used surface plasmon resonance. The GST-ZnF was immobilized on a CM-5 chip, and a flow of HA-monoubiquitin was injected at different concentrations, essentially as described before. 25 The calculated dissociation constant (K D ), 205 mM, for the ZnF --Ub complex (Supplementary Figure S1) is well within the low-affinity range of interactions compared with other UBDs. 26 To evaluate the biological significance of the recognition of ubiquitin by the ZnF, we co-transfected cells with EGFR, along with either WT or DZnF Cezanne-1. As expected, the WT form of Cezanne-1 inhibited ligand-dependent degradation of EGFR. However, DZnF failed to inhibit receptor degradation (Figure 4c ), in line with a critical role for ubiquitin binding. A similar analysis, in which we applied a more detailed time course, proposed that the ZnF is essential for Cezanne-1-mediated retardation of EGFR degradation (Figure 4d ), possibly by binding to the Asp-58 surface of ubiquitins decorating internalized EGFRs. In summary, our data indicate that the A20-like ZnF of Cezanne-1 contacts ubiquitin via Asp-58, and that the interfacing residue involves Tyr-810 of Cezanne-1. Moreover, the Asp-58/Tyr-810 interaction is necessary for the stabilizing effect of Cezanne-1 toward EGFR.
Cezanne-1 physically interacts with homologous to the E6-AP carboxyl terminus (HECT) domain ubiquitin ligases involved in EGFR endocytosis
Nedd4 and AIP4 are WW domain ubiquitin ligases, which share catalytic homologous to the E6-AP carboxyl terminus (HECT) domains (see a scheme of Nedd4 in Supplementary Figure S2a ) and regulate EGFR endocytosis by coupling to CBL. 27, 28 To investigate possible interactions with Cezanne-1, we performed co-immunoprecipitation experiments by co-overexpressing these proteins in HEK-293T cells. Cezanne-1 physically interacted with AIP4, as well as with both the intact and a catalytically disabled mutant of Nedd4 (Supplementary Figures S2b and c) . However, deletion of the WW domains of Nedd4 abolished interactions. These results are consistent with the findings reported by a previous mass-spectrometry study, 29 and they reinforce the notion that Cezanne-1 regulates receptor endocytosis.
Cezanne-1 associates with cellular proliferation, migration and malignancy of breast lesions To address the consequences of Cezanne-1-mediated stabilization of active EGFRs, we established HeLa clones stably overexpressing the enzyme, and performed a clonogenic assay under anchoragedependent conditions. As expected, overexpression of the DUB resulted in more abundant and larger colonies (Figure 5a ). The reason for these differences was provided by a cell growth assay: whereas the control cells reached saturation, overexpression of Cezanne-1 released cells from density-dependent arrest (Figure 5b) . Interestingly, stimulation with EGF exerted relatively minor effects on the cell growth under the conditions we examined. Hence, we tested the ability of EGF and Cezanne-1 to increase an alternative outcome, namely migration and invasion of mammary tumor cells. MDA-MB-231 cells were first transfected with siRNA oligonucleotides and 24 h later they were plated on porous filters, which were either uncoated (migration assay) or pre-coated with an extracellular matrix (Matrigel; invasion assay). Cells that migrated through the filter toward EGF in the lower compartment were stained and photographed (Figures 5c and d) . Importantly, pre-treatment with a pool of oligonucleotides directed at Cezanne-1 effectively reduced expression of the enzyme as determined by PCR (Figure 5e ), as well as reduced both invasion and migration (Figure 5f ), but once again EGF exerted only limited effects.
Because these observations raised the possibility that Cezanne-1 harbors attributes of an oncoprotein, we examined potential associations with markers of disease aggressiveness. To enable analyses of clinical specimens, we generated a monoclonal antibody by immunizing mice with a recombinant human Cezanne-1. Thereafter, we retrieved a breast tissue microarray, which included normal breast, fibrocystic mastopathy, atypical ductal hyperplasia, ductal and lobular carcinoma in situ and several types of invasive carcinoma. In addition to hematoxylin --eosin stains, immunohistochemical analyses were carried out using our anti-Cezanne-1 monoclonal antibody. Cezanne-1 expression was scored as strong (3), moderate (2), weak (1) or negative (Figure 6a) . The scores resulting from our analyses revealed consistently higher expression of Cezanne-1 in malignant mammary tissues, as compared with normal breast or benign disease (Figure 6b) . Notably, this increase in Cezanne-1 expression could be observed already in early forms of the disease, such as ductal carcinoma in situ and lobular carcinoma in situ, but we cannot exclude association of the DUB with signaling pathways other than EGFR. Taken together with our biochemical and cell growth analyses, these results strongly implicate Cezanne-1 in breast cancer progression.
The gene encoding Cezanne-1 is frequently amplified in mammary tumors, and enhanced levels of the respective mRNA predict shorter patient survival The remarkably variable abundance of Cezanne-1 in breast tissues (Figure 6b ) prompted us to analyze gene copy numbers in a collection of 60 human tumor cell lines (NCI-60). The corresponding array comparative genomic hybridization data indicated that the gene, which is localized to 1q21.2, is amplified in one third of the cell lines (Figure 7a and Supplementary Figure S3a) . It is notable that B50% of breast tumors present gains at 1q, whereas the short arm presents mostly losses. 30 --32 Indeed, immunoblotting of a set of tumor and normal mammary cell lines detected variable abundance of the characteristic bands of Cezanne-1 ( Supplementary Figures S3b and c) . Hence, in the next step we analyzed a cohort of 173 breast tumors reported by The Cancer Genome Atlas (http://cancergenome.nih.gov), and found that 32% presented a DNA amplification corresponding to the CEZ1 gene (Figure 7b ). We also analyzed the same cohort for correlation between mRNA levels and copy number of CEZ1, and found positive correlation (Pearson's correlation coefficient r ¼ 0.46, P ¼ 7.75e-11). Hence, we compared mRNA abundance in tumors versus the adjacent normal tissues. The results we obtained (Figure 7c ) clearly indicated that Cezanne-1 is overexpressed in tumors compared with paired adjacent normal tissues. Importantly, analysis of 148 breast cancer patients from the same cohort, for whom clinical data were available, revealed that high abundance of the corresponding mRNA predicts shorter patient survival time (Figure 7d) . Collectively, the results we obtained using clinical data offer a model attributing to receptor deubiquitination and escape from degradation critical roles in promoting tumor aggressiveness.
DISCUSSION
Early feedback loops controlling EGFR depend on covalent modifications, whereas late processes rely on newly synthesized proteins, and aberrant variants of both are implicated in cancer. 1 Concentrating on the early loops, we previously identified DEP-1, a tyrosine phosphatase often deleted in carcinomas, as an enzyme that inactivates EGFR. 33 Because phosphorylation and ubiquitination of EGFR are coupled, we assumed that the tumor suppressor function of DEP-1 would be mirrored by oncogenic functions of EGFR-specific DUBs. In line with this prediction, overexpression of the DUB we identified, Cezanne-1, is associated with a relatively aggressive course of breast cancers. Like DEP-1, Cezanne-1 assembles with EGFR before stimulation, and this physical interaction is enhanced by EGF (Figure 3a) , probably due to interactions of the two UBDs of Cezanne-1 with ubiquitins that decorate active EGFRs. Interestingly, our results attribute different binding specificities to the two UBDs of Cezanne-1: whereas the UBA binds with the canonical isoleucine-44 aspect of ubiquitin, the ZnF binds with aspartate-58. It is worth noting that A20, a negative regulator of the nuclear factor-kb pathway, shares with Cezanne-1 both a ZnF and a catalytic active deubiquitinating domain. This multifunctional enzyme functions as an editing enzyme: the enzyme first removes Lys-63-linked polyubiquitins from its substrate, RIP and then it attaches to RIP Lys-48-linked polyubiquitins via its ZnF. 34 Whether Cezanne-1 similarly edits ubiquitinated EGFRs remains an intriguing question. Our results propose that this DUB rapidly associates with active receptors, once they undergo ubiquitination. Subsequently, Cezanne-1 deubiquitinates the receptors, thereby delaying their degradation and prolonging growth and motility signals.
Certain genomic amplicons have been associated with vesicle recycling in tumors. 35 For example, 8p11-12 is frequently amplified in breast cancer. This region encodes the RAB-coupling protein, RCP, which confers oncogenic properties by shunting integrins and other receptors to a recycling route. 36 Likewise, RAB23 is encoded by the 6p11 amplicon and contributes to invasiveness of gastric cancer. 37 The long arm of chromosome 1 is involved in quantitative anomalies in at least 50% of breast tumors. 1q22 encodes RAB25, an oncogenic partner of RCP, which is overexpressed in breast and in ovarian cancer. 38 A family member of RAB25, called RAB11A, is overexpressed in ductal Amplifications are marked in red, deletions in green. The scale of colors is based on the log ratio between the respective cell line and a normal sample (log ratio of zero is shown in white). A CNV (at 149 400 000) deleted in 26 samples was not included. (b) DNA copy number of CEZ1 in tumors from breast cancer patients. The x-axis represents 173 patients, 56 of them have gained at least 1 extra copy of CEZ1. The y-axis represents log2 ratio of SNP intensity using paired blood-derived normal cells as control. The horizontal line represents log2 ratio value for three copies. (c) mRNA abundance of Cezanne-1 in pairs of a breast tumor and adjacent normal tissues from 24 breast cancer patients. The statistical P-value, determined by using the paired two-sample t-test, is indicated. (d) Kaplan --Meyer survival analysis was performed on 148 breast cancer patients. All patients were divided into high and low CEZ1 expression groups. The cutoff was optimized to achieve low P-value.
carcinoma in situ, 39 and yet another component of the recycling route, RAB4A, is encoded by the 1q42 amplicon. 32 The identification of Cezanne-1 as a regulator of EGFR trafficking adds a deubiquitination enzyme to the list of amplicon-encoded proteins that inhibit receptor degradation. Conceivably, amplicon-driven overexpression of Cezanne-1 results in deubiquitination of surface-bound or internalized EGFRs, thereby enhancing their firing in tumors. In addition, because recycling mechanisms are shared by several growth factor receptors and by adhesion molecules such as integrins, overexpression of Cezanne-1 is expected to enhance recycling of multiple endosomal cargos, especially in the leading edge of tumor cells, thereby promoting cellular motility and invasion. 40 Validation of these predictions is expected to motivate pharmacological strategies to intercept Cezanne-1 in tumors.
MATERIALS AND METHODS
Reagents and antibodies
Unless indicated, siRNA oligonucleotides were acquired from Dharmacon (Lafayette, CO, USA), antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and radioactive materials from IZOTOP (Budapest, Hungary).
DNA constructs and mutagenesis
The following plasmids were kind gifts: pHM6 encoding Cezanne-1 (Paul Evans; Imperial College, London, UK), pIND encoding Nedd4 (Marius Sudol; Danville, PA, USA) and pRK5 encoding AIP4 (Daniel Birnbaum; Marseille, France). Mutations were introduced using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Agilent Technologies, La Jolla, CA, USA). To clone GST fusion proteins, the relevant DNA sequences were cloned into a pGEX 4T1 vector (GE Healthcare, Uppsala, Sweden).
Cell lines and transfections
HeLa and KB cells were transfected using JetPEI (Polyplus transfection, Illkirch, France) or HiPerFect (Qiagen, Hilden, Germany). HEK-293T cells were transfected using calcium phosphate. To establish stable sub-lines, cells were co-transfected with a pLenti6 vector (Invitrogen, Carlsbad, CA, USA) harboring Cezanne-1 (Sigma, St Louis, MO, USA), together with a mixture of packaging plasmids. Following an overnight incubation, the medium were refreshed, and 48 h after transfection, virus-containing media were collected. Subsequently, target cells were infected with lentiviruses in the presence of hexadimethrine bromide (8 mg/ml). After 24 h, cells were subjected to drug selection for B10 days.
siRNA screen for DUBs KB cells were seeded in six-well plates and transfected with oligonucleotides of siRNA oligonucleotides (5 nM) targeting the majority of human DUBs or with control oligonucleotides. After 48 h, cells were stimulated with EGF (20 ng/ml) for up to 120 min. Whole cell lysates were immunoblotted with anti-EGFR antibodies to measure the degradation of EGFR.
Immunoprecipitation and immunoblotting
Cells were solubilized in lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid, 10 mM NaF and 30 mM b-glycerol phosphate) with freshly added 0.2 mM Na 3 VO 4 and a protease inhibitor cocktail. Electroblotted proteins were detected with antibodies linked to horseradish peroxidase, and visualized using reagents from Amersham (Buckinghamshire, UK).
Receptor downregulation assays
After 48 h transfection, cells were starved for 4 h and stimulated with EGF (2 ng/ml) at 37 1C. Subsequently, the cells were placed on ice, rinsed with binding buffer (Dulbecco's modified Eagle's medium containing 20 mM HEPES buffered at pH 7.5 and 1% albumin) and subjected to mild acid wash (0.2 M Na-acetate buffer pH 4.5, 0.5 M NaCl). Thereafter, cells were incubated at 4 1C with a radioactive EGF for 1.5 h. The control well was incubated with a radioactive EGF and an excess (50 Â ) of unlabeled EGF. Finally, cells were lysed in 1 M NaOH, and radioactivity was determined.
Colony formation and cell viability assays
For colony formation assays, cells (25 Â 10 3 ) were plated in 10-cm plates and grown for 7 days. Subsequently, cells were fixed and stained with Giemsa (0.2% in saline). For viability assays, cells were seeded in 96-well plates and cell proliferation was assayed every 24 h. In brief, 20 ml of 3-(4,5-dimethylthiazolyl-2)-2.5-diphenyltetrazolium bromide in phosphate-buffered saline was added to each well. Cells were incubated for 2 additional hours at 37 1C, 0.180 ml of solubilization solution (isopropanol in 40 mM HCl) was added and OD 595 was determined. The experiments were performed in quadruplets.
Surface plasmon resonance measurements
Binding of the ZnF to ubiquitin was analyzed at 25 1C, using a Biacore Â 100 system (GE Healthcare). Activation of the CM5 chip was achieved with 1:1 N-hydroxysuccinimide/1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. GST and a fusion protein comprising the ZnF of Cezanne-1 (8000 response units of each) were immobilized on the sensor chip by covalent linkage to the N terminus of GST. GST-fused proteins were passed over separate flow cells in 10 mM Na-acetate buffer (at pH 5.0), followed by a blocking step performed with ethanolamine (1M; pH 8.5). We measured the binding of mono-ubiquitin to the ZnF of Cezanne-1 by injecting it over the chip at different concentrations. Surface regeneration between subsequent injections of ubiquitin was done with 10 mM NaOH.
Immunohistochemical analyses
Before staining of tissue microarrays, antigen retrieval was achieved by pretreatment with citrate buffer for all the antibodies, except for Cezanne-1 staining, for which slides were pretreated with Pronase E. Staining was performed using a DAKO Tech Mate Horizon automated immunostainer (DAKO, Glosttrup, Denmark).
